FI20095751A - Ei Ad5 adenoviraaliset vektorit ja niihin liittyvät menetelmät ja käytöt - Google Patents

Ei Ad5 adenoviraaliset vektorit ja niihin liittyvät menetelmät ja käytöt Download PDF

Info

Publication number
FI20095751A
FI20095751A FI20095751A FI20095751A FI20095751A FI 20095751 A FI20095751 A FI 20095751A FI 20095751 A FI20095751 A FI 20095751A FI 20095751 A FI20095751 A FI 20095751A FI 20095751 A FI20095751 A FI 20095751A
Authority
FI
Finland
Prior art keywords
methods
well
adenoviral vectors
uses related
adenoviral
Prior art date
Application number
FI20095751A
Other languages
English (en)
Swedish (sv)
Other versions
FI121574B (fi
FI20095751A0 (fi
Inventor
Otto Hemminki
Gerd Bauerschmit
Vincenzo Cerullo
Sari Pesonen
Akseli Hemminki
Original Assignee
Oncos Therapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncos Therapeutics Oy filed Critical Oncos Therapeutics Oy
Publication of FI20095751A0 publication Critical patent/FI20095751A0/fi
Priority to FI20095751A priority Critical patent/FI121574B/fi
Priority to US13/147,288 priority patent/US20120063995A1/en
Priority to CA2750770A priority patent/CA2750770A1/en
Priority to AU2010209334A priority patent/AU2010209334A1/en
Priority to CN2010800087768A priority patent/CN102325887A/zh
Priority to SG2011055563A priority patent/SG173502A1/en
Priority to PCT/IB2010/050452 priority patent/WO2010086838A2/en
Priority to JP2011547047A priority patent/JP2012516682A/ja
Priority to EP10704194.9A priority patent/EP2391722B1/en
Priority to RU2011136280/10A priority patent/RU2011136280A/ru
Priority to BRPI1008159A priority patent/BRPI1008159A2/pt
Priority to KR1020117020181A priority patent/KR20110110371A/ko
Publication of FI20095751A publication Critical patent/FI20095751A/fi
Application granted granted Critical
Publication of FI121574B publication Critical patent/FI121574B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI20095751A 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä FI121574B (fi)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
PCT/IB2010/050452 WO2010086838A2 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
EP10704194.9A EP2391722B1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
AU2010209334A AU2010209334A1 (en) 2009-02-02 2010-02-02 Non-Ad5 adenoviral vectors and methods and uses related thereto
CN2010800087768A CN102325887A (zh) 2009-02-02 2010-02-02 非-Ad5腺病毒载体及与其相关的方法和用途
SG2011055563A SG173502A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
US13/147,288 US20120063995A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
JP2011547047A JP2012516682A (ja) 2009-02-02 2010-02-02 非Ａｄ５アデノウイルスベクター並びに前記に関連する方法および使用
CA2750770A CA2750770A1 (en) 2009-02-02 2010-02-02 Non-ad5 adenoviral vectors and methods and uses related thereto
RU2011136280/10A RU2011136280A (ru) 2009-02-02 2010-02-02 HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
BRPI1008159A BRPI1008159A2 (pt) 2009-02-02 2010-02-02 vetores adenovirais não-ad5 e métodos e usos relacionados aos mesmos
KR1020117020181A KR20110110371A (ko) 2009-02-02 2010-02-02 비-Ａｄ5 아데노바이러스 벡터 및 이와 관련된 방법 및 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset
FI20090030 2009-02-02
FI20095751 2009-07-02
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Publications (3)

Publication Number Publication Date
FI20095751A0 FI20095751A0 (fi) 2009-07-02
FI20095751A true FI20095751A (fi) 2010-08-03
FI121574B FI121574B (fi) 2011-01-14

Family

ID=40404558

Family Applications (2)

Application Number Title Priority Date Filing Date
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset
FI20095751A FI121574B (fi) 2009-02-02 2009-07-02 Ei-Ad5 adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI20090030A FI20090030A0 (fi) 2009-02-02 2009-02-02 Onkolyyttiset virukset

Country Status (12)

Country Link
US (1) US20120063995A1 (fi)
EP (1) EP2391722B1 (fi)
JP (1) JP2012516682A (fi)
KR (1) KR20110110371A (fi)
CN (1) CN102325887A (fi)
AU (1) AU2010209334A1 (fi)
BR (1) BRPI1008159A2 (fi)
CA (1) CA2750770A1 (fi)
FI (2) FI20090030A0 (fi)
RU (1) RU2011136280A (fi)
SG (1) SG173502A1 (fi)
WO (1) WO2010086838A2 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013118724A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы и связанные с ними способы и применения
SG11201508585PA (en) 2013-04-18 2015-11-27 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN104946602A (zh) * 2015-06-11 2015-09-30 华中科技大学同济医学院附属同济医院 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用
HUE053236T2 (hu) * 2016-09-12 2021-06-28 Targovax Oy Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
US20190352669A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
US20210015878A1 (en) * 2018-03-28 2021-01-21 Epicentrx, Inc. Personalized cancer vaccines
AU2019288277A1 (en) * 2018-06-19 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036989A1 (en) * 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof

Also Published As

Publication number Publication date
FI121574B (fi) 2011-01-14
CA2750770A1 (en) 2010-08-05
FI20095751A0 (fi) 2009-07-02
EP2391722B1 (en) 2014-06-11
CN102325887A (zh) 2012-01-18
JP2012516682A (ja) 2012-07-26
WO2010086838A3 (en) 2010-11-25
KR20110110371A (ko) 2011-10-06
FI20090030A0 (fi) 2009-02-02
US20120063995A1 (en) 2012-03-15
EP2391722A2 (en) 2011-12-07
WO2010086838A2 (en) 2010-08-05
RU2011136280A (ru) 2013-03-10
BRPI1008159A2 (pt) 2016-03-29
SG173502A1 (en) 2011-09-29
AU2010209334A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
BR112012011629A2 (pt) nanopapel forte
DK2435742T3 (da) Bøjebegrænser
DK2145819T3 (da) Fortøjningsaggregat
FI20086175A0 (fi) Alus
FI20095751A (fi) Ei Ad5 adenoviraaliset vektorit ja niihin liittyvät menetelmät ja käytöt
DK2349829T3 (da) Flydende tørdok
DK3075858T3 (da) Mammalia-ekspressionsvektor
BRPI0912152A2 (pt) umbilical
DK2609083T3 (da) Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer
BRPI0815733A2 (pt) Estrutura flutuante.
DK2609086T3 (da) Substituerede 2-oxo- og 2-thioxo-dihydroquinolin-3-carboxamider som KCNQ2/3 modulatorer
FI20100404A0 (fi) Yhteysalus
IT1401836B1 (it) Tesa portaocchiali
FR2968020B1 (fr) Brise-lames flottant
FI20105147A0 (fi) Keulaluukku
FI20095971A0 (fi) Kannettava kosteusmittari
FI20100353A (fi) Iskulaite
IT1400614B1 (it) Imbarcazione
FI20105991A0 (fi) Adenovirusvektoreita ja menetelmiä ja käyttöjä niihin liittyen
FI20105988A (fi) Adenovirusvektoreita ja menetelmiä ja käyttöjä niihin liittyen
UA18434S (uk) Профіль стикувальний
UA18417S (uk) Профіль стикувальний
UA18629S (uk) Профіль стикувальний
UA18433S (uk) Профіль стикувальний
UA18436S (uk) Профіль стикувальний

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ONCOS THERAPEUTICS OY

Free format text: ONCOS THERAPEUTICS OY

FG Patent granted

Ref document number: 121574

Country of ref document: FI

MM Patent lapsed